Soft Street S55 Lefferts Avenue Brooklyn, NY 11225 Suite 601 New York, NY 10019	I O N Mi	ission Medica	233 Union Ave Suite 207 Holbrook, NY 11741 Long Beach 917 Beech Street	CF104 Forest Hills, NY 11375 Scarsdale 495 Central Park Avenue Suite 205 Scarsdale, NY 10583 Riverhead 1228 E Main Street	New York, NY 5 Towns 141 Washington A Cedarhurst, NY 1
LEQEMBI MEDICATION OR	DER D	ate:	Long Beach, NY 11561	Suite A Riverhead, NY 11901	
•	NT INFORM	ATION			
Name:	DOB:	AHON			
Allergies:	Date of Referr	al:			
	ERRAL STATUS		ti Onder		
□ New Referral □ Dose or Frequency Change	☐ Order Renewa	II U Discontii	nuation Order		
☐ G30.0 Alzheimer's with early onset (at <65y/o)			er Alzheimer's disea	ise	
 Details Needed for Therapy Supporting documentation of patient's neurological hist Documentation of the presence of amyloid beta patho Brain MRI from within the past year. Brain MRI must be There is a risk of Amyloid Related Imaging Abnormality during therapy, and the decision on whether to susper The MRI reports and orderin provider written evaluated IV Premedication Order (optional) IV pre-medications 	ology. De provided prior to ties (ARIA). Testing the therapy, remained therapy to the province	to the 5th, 7th and g for and clinical states the sole responded before the sole 15 minutes pr	nd 14th infusions. I evaluation regardi nsibility of the orde e start of each roun	ering provider. d of therapy. fusion treatmen	t.
 Details Needed for Therapy Supporting documentation of patient's neurological hist Documentation of the presence of amyloid beta patho Brain MRI from within the past year. Brain MRI must be There is a risk of Amyloid Related Imaging Abnormality during therapy, and the decision on whether to susper The MRI reports and orderin provider written evaluated IV Premedication Order (optional) IV pre-medications 	ology. pe provided prior to ties (ARIA). Testing and therapy, remaine tions must be provided to be administered thasone	to the 5th, 7th and g for and clinicans the sole responded before the ed 15 minutes prome mg —mg	nd 14th infusions. I evaluation regardinsibility of the order start of each rounding to start of the initial to start of the i	ering provider. d of therapy. fusion treatmen em	<i>t</i> .
■ Details Needed for Therapy Supporting documentation of patient's neurological hist Documentation of the presence of amyloid beta pathor Brain MRI from within the past year. Brain MRI must be There is a risk of Amyloid Related Imaging Abnormalit during therapy, and the decision on whether to susper The MRI reports and orderin provider written evaluate IV Premedication Order (optional) IV pre-medications □ Diphenhydraminemg □ Dexamete	ology. pe provided prior to ties (ARIA). Testing and therapy, remaine tions must be provided to be administered thasone	to the 5th, 7th and g for and clinicans the sole responded before the ed 15 minutes prome mg —mg	nd 14th infusions. I evaluation regardinsibility of the order estart of each round ior to start of the info	ering provider. d of therapy. fusion treatmen em	<i>t</i> .
■ Details Needed for Therapy Supporting documentation of patient's neurological hist • Documentation of the presence of amyloid beta pathor • Brain MRI from within the past year. Brain MRI must be • There is a risk of Amyloid Related Imaging Abnormalited during therapy, and the decision on whether to suspere The MRI reports and orderin provider written evaluated in the image of	ology. pe provided prior to ties (ARIA). Testing and therapy, remain tions must be provided to be administered thasone	to the 5th, 7th and g for and clinical ins the sole responded before the ed 15 minutes promise mg	nd 14th infusions. I evaluation regardinsibility of the order estart of each round ior to start of the info	ering provider. d of therapy. fusion treatmen emg	<i>t.</i>
■ Details Needed for Therapy Supporting documentation of patient's neurological hist Documentation of the presence of amyloid beta pathor Brain MRI from within the past year. Brain MRI must be There is a risk of Amyloid Related Imaging Abnormalit during therapy, and the decision on whether to susper The MRI reports and orderin provider written evaluate IV Premedication Order (optional) IV pre-medications Diphenhydraminemg Dexamet Leqembi (lecanemab-irmb) Medication Order Only one course can be selected per order form.	plogy. pe provided prior to ties (ARIA). Testing and therapy, remain tions must be provided to be administered thasone Patient's heightham 10m 10m bag and infused on the provided to the p	to the 5th, 7th and g for and clinical as the sole responded before the ed 15 minutes promption in ft/in:	nd 14th infusions. I evaluation regardinsibility of the order start of each round of the initial	ering provider. d of therapy. fusion treatmen emg in lbs: es number 7 – 1: es number 14 – 2: a 0.2 micron in-	t. g 3 20 -line
 ■ Details Needed for Therapy Supporting documentation of patient's neurological hist • Documentation of the presence of amyloid beta pathor • Brain MRI from within the past year. Brain MRI must be • There is a risk of Amyloid Related Imaging Abnormality during therapy, and the decision on whether to susper The MRI reports and orderin provider written evaluated. ■ IV Premedication Order (optional) IV pre-medications. □ Diphenhydraminemg □ Dexamet. ■ Leqembi (lecanemab-irmb) Medication Order. □ Only one course can be selected per order form. □ 10mg/kg IV every 2 weeks for treatments number 1 – 4 □ 10mg/kg IV every 2 weeks for treatments number 5 – 6 Medication shall be added to a 250ml 0.9% NaCl infusion filter attached. Post infusion flush with normal saline. Checked 	plogy. pe provided prior to ties (ARIA). Testing and therapy, remain tions must be provided to be administered that the provided that the provided to be administered that the provided that the	to the 5th, 7th and g for and clinical as the sole responded before the ed 15 minutes promption in ft/in:	nd 14th infusions. I evaluation regardinsibility of the order start of each round of the initial	ering provider. d of therapy. fusion treatmen emg in lbs: es number 7 – 1: es number 14 – 2: a 0.2 micron in-	t. g 3 20 -line
■ Details Needed for Therapy Supporting documentation of patient's neurological hist • Documentation of the presence of amyloid beta pathor • Brain MRI from within the past year. Brain MRI must be • There is a risk of Amyloid Related Imaging Abnormalit during therapy, and the decision on whether to susper The MRI reports and orderin provider written evaluate ■ IV Premedication Order (optional) IV pre-medications □ Diphenhydraminemg □ Dexamet ■ Leqembi (lecanemab-irmb) Medication Order Only one course can be selected per order form. □ 10mg/kg IV every 2 weeks for treatments number 1 – 4 □ 10mg/kg IV every 2 weeks for treatments number 5 – 6 Medication shall be added to a 250ml 0.9% NaCl infusion filter attached. Post infusion flush with normal saline. Check	plogy. pe provided prior to ties (ARIA). Testing and therapy, remain tions must be provided to be administered thasone Patient's heightout 10m 10m 10m 10m ck vitals and monitions and monitions and monitions and monitions are provided to the provided	to the 5th, 7th and g for and clinical is the sole responsible of the sole of	nd 14th infusions. I evaluation regardinsibility of the order that the order to start of the initial Methylprednisolone. Patient's weight weeks for treatment weeks for treatment that IV line shall have a symptoms at start,	ering provider. d of therapy. fusion treatmen emg in lbs: es number 7 – 1: es number 14 – 2: a 0.2 micron inthroughout infu	t. g 3 20 -line ision,

Provider's Signature: X Name: ______ Date: ______

Address: ______

Phone: _____ Fax: _____ NPI #: ____ License: ______

Best Contact Person in Office: ______ Direct Phone Line to Contact Person: ______

■ STANDARD DOCUMENTATION TO INCLUDE:

- Patient demographics and insurance, including card scans (both medical and pharmacy benefit cards, both sides).
- Most recent chart notes and, if available, last history and physical. All relevant scans, tests and laboratory results.
- If new medication for patient, chart notes which include decision to begin treatment. If not, provide last treatment date.